SALT LAKE CITY, Nov. 10, 2025 — Leads & Copy — Myriad Genetics, Inc. (NASDAQ: MYGN) announced the expansion of its MyRisk® Hereditary Cancer Test to include genes referenced in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and guidelines from the American Society of Clinical Oncology (ASCO) today.
The company said these genes are strongly associated with cancer risk and may have clear clinical actionability, supporting the goal that each addition to the panel provides meaningful insights for patient care. The updated MyRisk panel now includes 63 genes across more than 11 cancer types, reflecting Myriad’s commitment to meeting evolving clinical needs.
According to Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics, while many labs can detect DNA variants, Myriad excels at interpreting those variants. Muzzey said medical societies recommend genes for testing when they influence treatment decisions, and those are the genes Myriad prioritizes in the MyRisk Test. He added that he is delighted that these clinically significant genes are now part of the core MyRisk panel and that as guidelines evolve, Myriad remains committed to providing clinicians and genetic counselors with insights of high clinical utility to guide patient care.
The MyRisk Test is designed to deliver clinical value at every step of the cancer care continuum by helping treatment decisions, surveillance planning, and family risk assessment across multiple cancer types. Clinicians can conveniently order, receive, and review expanded MyRisk Test results directly through paper Test Requisition Forms and reports, the Myriad patient portal, and several electronic medical record platforms, including EPIC and OncoEMR. The full gene list and associated medical management recommendations can be viewed at the Myriad gene table.
NCCN makes no warranties regarding their content, use, or application and disclaims any responsibility for their use in any way.
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs.
Investor Contact:
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact:
Kate Schraml
(224) 875-4493
PR@myriad.com
Safe Harbor Statement: This press release contains forward-looking statements that are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation to update or alter any forward-looking statements.
Source: Myriad Genetics
